arrow
S

Seung Joon Kim

seoul st mary's hospital college of medicine the catholic university of korea
H指数:29
被引数:3,224

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes of Brigatinib Compared to Alectinib as a Second-Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients

与阿来替尼相比,brigatinib作为克唑替尼后二线疗法在晚期间变性淋巴瘤激酶阳性非小细胞肺癌患者中的真实世界疗效。

2025-10-010
OAAI
Interleukin-12 signaling drives Alzheimer's disease pathology through disrupting neuronal and oligodendrocyte homeostasis

白介素-12信号通过破坏神经元和少突胶质细胞的稳态来驱动阿尔茨海默病病理学。

2025-03-130
OA
Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter Trial

Bojungikki-Tang草药 medicine 联合 Pembrolizumab 与 Pembrolizumab 单药治疗对 IV 期非小细胞肺癌的疗效与安全性:一项随机、开放标签、双臂、多中心试验的研究方案

2025-02-220
OA
Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion
2024-05-210
OAAI
Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC) (vol 42, 309, 2023)
2023-12-060
OAAI
Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC)
2023-11-227
OAAI
Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data

真实世界一线阿法替尼治疗晚期EGFR突变阳性非小细胞肺癌: 更新的生存数据

2023-11-010
OAAI
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors

EGFR突变非小细胞肺癌脑转移患者一线阿法替尼的真实世界分析: 生存和预后因素

2023-06-012
OAAI